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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Available evidence suggests that the M3
receptor on endothelial cells is responsible
for acetylcholine (Ach)-dependent
vasodilatation.
• Data from human studies only provide
indirect evidence for this, and results are
more difficult to interpret.
WHAT THIS STUDY ADDS
• This study used the new M3 receptor
antagonist darifenacin as a pharmacological
‘tool’ to investigate the role of M3 receptor
in the human forearm circulation.
• It provides evidence for a major role for the
M3 receptors in ACh-dependent
vasodilatation in the forearm vascular bed.
AIMS
Acetylcholine (ACh) is a muscarinic agonist that causes
receptor-mediated, endothelium-dependent vasodilatation in the
forearm vasculature. Previous indirect evidence suggests this effect
may be mediated by muscarinic M3 receptors. Darifenacin is a recently
developed antimuscarinic drug with greater M3 selectivity, and our
main objective was to investigate whether darifenacin affects
dose-dependent vasodilatation to ACh in the forearm circulation.
METHODS
Healthy subjects were enrolled in two studies designed to assess
the effects of atropine and darifenacin on the forearm blood flow
(FBF) response to ACh.
RESULTS
In both studies ACh caused similar dose-dependent vasoditation in
the forearm vasculature. In study I (5 subjects), the FBF response to
ACh was largely attenuated by pretreatment with the nonselective
muscarinic antagonist atropine. In study II (10 subjects), oral
administration of darifenacin 15 mg for 1 week significantly reduced
the FBF dose-dependent response to ACh 20 mg min-1 {mean difference
from placebo 5.8 [95% confidence interval (CI) 3.1, 8.7] ml min-1 per
100 ml of forearm volume, P < 0.001} and to ACh 60 mg min-1 [mean
difference from placebo 5.9 (95% CI 3.1, 8.7) ml min-1 per 100 ml of
forearm volume, P < 0.001]. After darifenacin, the AUC of change in FBF
from baseline was reduced by almost 50% compared with placebo.
CONCLUSIONS
These results suggest that, in the forearm vasculature, muscarinic M3
receptors play a major role in ACh-induced endothelium-mediated
vasodilatation.
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Introduction
Muscarinic receptors present on vascular endothelial
cells are associated with acetylcholine (ACh)-dependent
vasodilatation [1]. It is not clear which muscarinic (M)
receptor subtype mediates the vasodilator effect of ACh,
although previous studies have suggested that, in most
vascular preparations from animals, the M3 receptor
present on endothelial cells is responsible for this [2, 3].
With regard to human vessels, fewer data are available,
sometimes with conflicting results, depending on the
vascular bed investigated [4, 5].
Darifenacin is a recently introduced muscarinic antago-
nist with high affinity and selectivity for the M3 receptor [6]
and is clinically used for the treatment of the symptoms of
overactive bladder (OAB) [7]. We hypothesized that ACh
acts primarily as an M3 agonist in the vascular endothelium
of humans, and darifenacin would reduce or abolish ACh-
mediated vasodilatation.The main aim of the study was to
investigate whether darifenacin affects dose-dependent
vasodilatation to ACh in the forearm circulation.
Methods
Subjects
Healthy, nonsmoking, men were recruited from the com-
munity and enrolled in the study. The study was under-
taken with the approval of the local research ethics
committee and in accordance with the Declaration of Hel-
sinki. Written informed consent was obtained from each
subject before entry into the study.
Measurements
Arterial vasodilatation in the forearm was measured as
change in forearm blood flow (FBF) using the venous
occlusion plethysmography technique, as previously
described [8].
Drugs
Atropine, a nonselective muscarinic antagonist, was used
in study I as an active control to confirm the muscarinic
nature of the response to ACh.The M3 selective antagonist
darifenacin was used in study II. Darifenacin (Emselex®) is
clinically available as prolonged-release tablets at two
doses, 7.5 and 15 mg. In our study the highest (15 mg) of
the two recommended doses was used, and administered
orally once daily. This dose was chosen on the basis of
available evidence suggesting that improvement of OAB
symptoms with darifenacin is dose-dependent [9]. This
same dose has also been previously used in healthy volun-
teer studies to assess the pharmacodynamic effects of
darifenacin, suggesting its M3 selectivity when compared
with a selective M1/M2 antagonist [10].There is no available
evidence indicating that darifenacin has nonmuscarinic
effects. Previous receptor-binding studies have analysed
the affinity of darifenacin for the muscarinic receptors
[antagonist binding affinity estimates (pKi values, nm): 7.8
for M1, 7.0 for M2, 8.8 for M3, 7.7 for M4 and 8.0 for M5] [11]
and also reported selectivity differences, showing that
darifenacin is more selective for the M3 receptors, with a
selectivity at M3 receptors that is 9.3 times that at M1 recep-
tors, 59 times that at M2 or M4, and 12 times that at M5
receptors [12].
ACh was purchased from Clinalfa (Läufelfingen,
Switzerland); atropine sulphate (Antigen Pharmaceuticals
Ltd, Roscrea, Ireland) was purchased from the local hospital
pharmacy. Both agents were used after dilution in saline
(Baxter Healthcare Ltd,Thetford, UK).The doses of ACh and
atropine used were selected on the basis of previous pub-
lished data [13] and confirmed by pilot studies conducted
in healthy volunteers (data not shown).
Study I
This study was undertaken in order to confirm the effect of
the nonselective muscarinic receptor antagonist atropine
on ACh-mediated vasodilatation in five healthy subjects.
On the study day, after cannulation of the brachial artery
and baseline FBF measurements, FBF responses to two
doses of ACh (6 and 20 mg min-1) were assessed before and
after atropine infusion (0.2 mg).
Study II
The effect of a 1-week period of treatment with darifenacin
was investigated in a two-way, double-blind, randomized,
placebo-controlled, crossover FBF study.Ten subjects were
randomized to receive either placebo or darifenacin 15 mg
orally once daily for 1 week. At day 8 of each arm of the
study, separated by at least 1 week, subjects received a
6-min intra-arterial infusion of ACh at five consecutive and
incremental doses (0.6, 2, 6, 20 and 60 mg min-1).
Statistical analysis
Results are expressed as mean  SEM. FBF data are pre-
sented as changes in absolute blood flow (ml min-1 per
100 ml of forearm volume) in the infused arm [8]. In study
II, responses to ACh after darifenacin and placebo were
also quantified as area under the curve (AUC) of change in
absolute FBF from baseline, expressed in arbitrary units.
Comparisons were made with repeated measures ANOVA
and two-tailed Student’s t-test, as appropriate. Statistical
analysis was performed with Graph-Pad Prism (GraphPad
Software Inc., San Diego, CA, USA). Significance was
accepted at the 5% level in all cases.
Results
Table 1 shows characteristics of the study participants.
The only side-effect reported during treatment with
darifenacin was dry mouth, which occurred in two of the
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ten subjects enrolled in study II. Blood pressure and heart
rate did not change during any study day comparing base-
line and post-treatment values.
Study I
ACh dose-dependently increased FBF in the infused arm
(P < 0.001, ANOVA). Pretreatment with atropine significantly
decreased the vasodilator response to both doses of ACh
(P < 0.001, ANOVA) (Figure 1a).
Study II
ACh dose-dependently increased FBF in the infused arm
(P < 0.0001, ANOVA). Pretreatment with darifenacin signifi-
cantly decreased the vasodilator response to ACh
20 mg min-1 {mean difference from placebo 5.8 [95% con-
fidence interval (CI) 3.1, 8.7] ml min-1 per 100 ml of forearm
volume, P < 0.001} and to ACh 60 mg min-1 [mean differ-
ence from placebo 5.9 (95% CI 3.1, 8.7) ml min-1 per 100 ml
of forearm volume, P < 0.001] (Figure 1b). After darifenacin,
the AUC of change in FBF from baseline was reduced by
almost 50% [mean difference in AUC from placebo 291.6
(95% CI 121.7, 461.5) arbitrary units, P = 0.003].
Discussion
The main aim of this study was to investigate the effects of
darifenacin on the dose–response curve of ACh-mediated
vasodilatation in the forearm vasculature. Our results show
that pretreatment with darifenacin substantially reduced
the response to ACh, indicating the importance of the
M3 receptors in mediating ACh-induced vasodilatation.
However, darifenacin did not completely abolish vasodila-
tation to ACh, and one possible explanation is that other
muscarinic receptor subtypes located in the vessel wall
may contribute to this response. This is supported by the
results of study I, in which atropine almost abolished the
vasodilator response to intra-arterial infusion of ACh. It is
also possible that nonmuscarinic receptors are involved in
the residual ACh-dependent vasodilatation and might
contribute to explaining our findings.
From a clinical point of view, there are also possible
practical implications: indeed, our results suggest that
darifenacin may interfere with endothelial function
testing, and in people taking darifenacin, assessment of
endothelial function with ACh may therefore be con-
founded by the use of this drug.
In conclusion, results from this study indicate that, in
the human forearm vascular bed, the muscarinic M3 recep-
tors play a major role in ACh-mediated vasodilatation.
Study limitations
Although our study provides evidence for a major role for
M3 receptor in ACh-mediated vasodilatation, we are aware
Table 1
Clinical characteristics of the study subjects
Study I Study II
Number of subjects 5 10
Age, years 28 (4) 37 (4)
Systolic BP before/after treatment
(II), mmHg
115 (3) 117 (2)/113 (2)
Diastolic BP before/after
treatment (II), mmHg
72 (3) 69 (3)/66 (4)
BMI, kg m-2 22 (1) 24 (1)
Data are mean (SEM). BMI, body mass index; BP, blood pressure. 0
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Figure 1
(a) Changes in absolute blood flow (ml min-1 per 100 ml of forearm
volume) in the infused arm in response to acetylcholine (Ach) infusion
(6 and 20 mg min-1) before and after atropine. Data are mean SEM.
P < 0.001 ACh vs. ACh plus atropine. (b) Changes in absolute blood flow
(ml min-1 per 100 ml of forearm volume) in the infused arm in response to
ACh infusion (0.6, 2, 6, 20 and 60 mg min-1) after a 1-week period of treat-
ment with darifenacin compared with placebo. Data are mean SEM.
P < 0.001 darifenacin vs. placebo
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of some limitations that need to be addressed in future
studies. First, plasma darifenacin levels were not measured
in our subjects, and selectivity of the drug at the dose used
for M3 receptors on the endothelium is not known. It is
therefore possible that concentrations required to block
the M3 receptors may also result in blockade of other mus-
carinic receptors. However, in Phase III studies conducted
in patients [9] and healthy volunteers [10] darifenacin
15 mg showed a selective M3 profile when compared with
a M1/M2 antagonist.
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